RPL13AP20

Across TCGA pan-cancer cohorts, RPL13AP20 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPL13AP20 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RPL13AP20 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPL13AP20 expression acts as an unfavorable survival marker.

STAD and LUSC are the cancer types where RPL13AP20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
LUSC	OS	Median	All	0.247	0.676	.027	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RPL13AP20–STAD (OS)

Open the STAD breakdown →